Victoria Katherine Honnell, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Retina | 3 | 2024 | 2662 | 0.870 |
Why?
|
| Gene Expression Regulation, Developmental | 3 | 2024 | 3610 | 0.850 |
Why?
|
| Neurogenesis | 2 | 2024 | 864 | 0.640 |
Why?
|
| Enhancer Elements, Genetic | 2 | 2024 | 1367 | 0.600 |
Why?
|
| Homeodomain Proteins | 3 | 2024 | 2430 | 0.600 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2022 | 792 | 0.590 |
Why?
|
| Rhabdomyosarcoma | 3 | 2022 | 358 | 0.320 |
Why?
|
| Transcription Factors | 3 | 2024 | 12171 | 0.290 |
Why?
|
| Microphthalmos | 1 | 2024 | 58 | 0.230 |
Why?
|
| Rhabdomyosarcoma, Alveolar | 1 | 2022 | 43 | 0.200 |
Why?
|
| Euchromatin | 1 | 2019 | 54 | 0.170 |
Why?
|
| Retinal Bipolar Cells | 1 | 2019 | 46 | 0.160 |
Why?
|
| Epigenomics | 2 | 2022 | 960 | 0.150 |
Why?
|
| Organoids | 1 | 2024 | 743 | 0.150 |
Why?
|
| Muscle Neoplasms | 1 | 2018 | 130 | 0.140 |
Why?
|
| Heterochromatin | 1 | 2019 | 294 | 0.140 |
Why?
|
| Neuroglia | 1 | 2022 | 960 | 0.130 |
Why?
|
| Evolution, Molecular | 1 | 2024 | 1896 | 0.130 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2018 | 3612 | 0.100 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2018 | 2433 | 0.100 |
Why?
|
| Cell Cycle Proteins | 2 | 2018 | 3445 | 0.080 |
Why?
|
| Mice | 5 | 2024 | 82049 | 0.080 |
Why?
|
| Stem Cells | 1 | 2022 | 3538 | 0.080 |
Why?
|
| Nuclear Proteins | 2 | 2018 | 5804 | 0.070 |
Why?
|
| Cell Proliferation | 1 | 2022 | 10478 | 0.060 |
Why?
|
| Animals | 5 | 2024 | 169285 | 0.060 |
Why?
|
| Cell Differentiation | 1 | 2022 | 11677 | 0.060 |
Why?
|
| Neurons | 1 | 2022 | 9514 | 0.050 |
Why?
|
| Paired Box Transcription Factors | 1 | 2022 | 206 | 0.050 |
Why?
|
| Jumonji Domain-Containing Histone Demethylases | 1 | 2022 | 168 | 0.050 |
Why?
|
| Nuclear Lamina | 1 | 2019 | 46 | 0.040 |
Why?
|
| Retinal Rod Photoreceptor Cells | 1 | 2019 | 204 | 0.040 |
Why?
|
| Unfolded Protein Response | 1 | 2018 | 239 | 0.030 |
Why?
|
| Antineoplastic Agents | 1 | 2018 | 13677 | 0.030 |
Why?
|
| Vincristine | 1 | 2017 | 1040 | 0.030 |
Why?
|
| Forkhead Transcription Factors | 1 | 2022 | 1625 | 0.030 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2019 | 859 | 0.030 |
Why?
|
| Pyrimidinones | 1 | 2017 | 386 | 0.030 |
Why?
|
| Hydroxamic Acids | 1 | 2017 | 483 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2022 | 8648 | 0.030 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2022 | 1613 | 0.030 |
Why?
|
| Clone Cells | 1 | 2017 | 1670 | 0.030 |
Why?
|
| Camptothecin | 1 | 2017 | 600 | 0.030 |
Why?
|
| Cell Line, Tumor | 2 | 2022 | 17142 | 0.030 |
Why?
|
| High-Throughput Screening Assays | 1 | 2017 | 942 | 0.020 |
Why?
|
| Gene Regulatory Networks | 1 | 2019 | 1752 | 0.020 |
Why?
|
| Indoles | 1 | 2017 | 1836 | 0.020 |
Why?
|
| Neoplasms | 1 | 2017 | 22371 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2019 | 5797 | 0.020 |
Why?
|
| Single-Cell Analysis | 1 | 2019 | 2540 | 0.020 |
Why?
|
| Chromatin | 1 | 2019 | 2981 | 0.020 |
Why?
|
| Female | 3 | 2022 | 397187 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2017 | 6316 | 0.020 |
Why?
|
| Child | 3 | 2022 | 80917 | 0.020 |
Why?
|
| Molecular Targeted Therapy | 1 | 2018 | 2830 | 0.020 |
Why?
|
| Pyrazoles | 1 | 2017 | 2028 | 0.020 |
Why?
|
| Male | 2 | 2022 | 364731 | 0.020 |
Why?
|
| Humans | 4 | 2024 | 768171 | 0.020 |
Why?
|
| Pyrimidines | 1 | 2017 | 3048 | 0.020 |
Why?
|
| Proteomics | 1 | 2018 | 3912 | 0.010 |
Why?
|
| Epigenesis, Genetic | 1 | 2017 | 3833 | 0.010 |
Why?
|
| Genomics | 1 | 2018 | 5926 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2018 | 9540 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2018 | 23648 | 0.010 |
Why?
|